Mustang Bio Receives Positive Listing Determination from Nasdaq
12 Novembre 2024 - 2:30PM
Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a
clinical-stage biopharmaceutical company focused on translating
today’s medical breakthroughs in cell therapies into potential
cures for difficult-to-treat cancers, today announced that by
decision dated November 8, 2024, the Nasdaq Hearings Panel granted
the Company’s request for an extension to evidence compliance with
all applicable criteria for continued listing on The Nasdaq Capital
Market, including the $1.00 bid price requirement through January
31, 2025 and the $2.5 million stockholders’ equity requirement
through February 18, 2025. The Company is considering all available
options that may enable it to timely evidence compliance with the
continued listing criteria and maintain its listing on Nasdaq;
however, there can be no assurance that the Company will be able to
do so.
About Mustang Bio Mustang Bio,
Inc. is a clinical-stage biopharmaceutical company focused on
translating today’s medical breakthroughs in cell therapies into
potential cures for difficult-to-treat cancers. Mustang aims to
acquire rights to these technologies by licensing or otherwise
acquiring an ownership interest, to fund research and development,
and to outlicense or bring the technologies to market. Mustang has
partnered with top medical institutions to advance the development
of CAR-T therapies. Mustang’s common stock is registered under the
Securities Exchange Act of 1934, as amended, and Mustang files
periodic reports with the U.S. Securities and Exchange Commission
(“SEC”). Mustang was founded by Fortress Biotech, Inc. (Nasdaq:
FBIO). For more information, visit www.mustangbio.com.
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements, which are often indicated by terms such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions. The
Company’s forward-looking statements, include, but are not limited
to, any statements relating to our growth strategy and product
development programs, including the timing of and our ability to
make regulatory filings such as INDs and other applications and to
obtain regulatory approvals for our product candidates, statements
concerning the potential of therapies and product candidates and
any other statements that are not historical facts. Actual events
or results may differ materially from those described in this press
release due to a number of risks and uncertainties. Risks and
uncertainties include, among other things, our need for substantial
additional funds in the immediate future, risks that any actual or
potential clinical trials described herein may not initiate or
complete in sufficient timeframes to advance the Company’s
corporate objectives, or at all, or that promising early results
obtained therefrom may not be replicable, risks related to the
satisfaction of the conditions necessary to transfer the lease of
the Company’s manufacturing facility to a potential transferee and
receive the contingent payment in connection with the sale of such
facility in the anticipated timeframe or at all; whether the
purchaser of the Company’s manufacturing facility is able to
successfully perform its obligation to produce the Company’s
products under the manufacturing services agreement on a timely
basis and to acceptable standards; disruption from the sale of the
Company’s manufacturing facility making it more difficult to
maintain business and operational relationships; negative effects
of the announcement or the consummation of the transaction on the
market price of the Company’s common stock; significant transaction
costs; the development stage of the Company’s primary product
candidates, our ability to obtain, perform under, and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; government regulation; patent and intellectual
property matters; competition; as well as other risks described in
Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K
filed on March 11, 2024, subsequent Reports on Form 10-Q, and our
other filings we make with the SEC. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law, and we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995.
Company Contacts: Jaclyn Jaffe and Nicole
McCloskeyMustang Bio, Inc.(781) 652-4500ir@mustangbio.com
Grafico Azioni Mustang Bio (NASDAQ:MBIO)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Mustang Bio (NASDAQ:MBIO)
Storico
Da Dic 2023 a Dic 2024